Main Highlights
- The 5tth patient has been treated in the ongoing PANCOSIL Investigator-Initiated Clinical Trial.
- PANCOSIL is a Netherlands-based Investigator-Initiated Clinical Trial conducted at AMC Medical Centre in Amsterdam in collaboration with OncoSil Medical.
- This Trial is designed for patients with locally advanced unresectable pancreatic cancer, testing the safety and feasibility of CT-guided percutaneous radionuclide therapy (RNT) with the OncoSil™ device
- A total of 20 patients will be treated with the OncoSil™ device in the PANCOSIL Trial.
What happened?
Pancreatic cancer treatment device company OncoSil Medical (ASX: OSL) has treated its fifth patient under the PANCOSIL clinical trial. The Netherlands-based investigator started clinical trials that are conducted at the AMC Medical Centre in Amsterdam in collaboration with Oncosil Medical.
Why it Matters?
- The PANCOSIL Trial aims to assess the safety and feasibility of CT-guided percutaneous radionuclide therapy using the OncoSil device in patients with non-progressive locally advanced pancreatic cancer. A strong safety record will allow the product to be used in Europe and across a range of markets.
- The trial aims to treat 20 patients with the OncoSil device through percutaneous application.
- The company said the fifth patient in the trial received treatment on 28 May. The trial is proceeding as expected and the fifth patient has been treated today. This marks an important step in the trial.
The company said the next step in the trial involves a protocol amendment to remove the requirement for mandatory general anesthesia. It said the amendment aims to allow treatment under conscious sedation, subject to approval from the ethics committee. The proposed change is expected to enhance patient comfort and expedite patient recruitment into the trial.
What Next for OncoSil Medical?
As the fifth person has been treated under the PANCOSIL trial, the next step in the trial involves a protocol amendment to remove the requirement for mandatory general anesthesia. This amendment is expected to allow treatment under conscious sedation, subject to approval from the Ethics Committee. The proposed change is expected to improve patient comfort and expedite patient recruitment into the trial. Oncosil Medical Ltd remains committed to improving the treatment of locally advanced pancreatic cancer and looks forward to providing further updates as the PANCOSIL Trial progresses.
